Ratings by Cantor Fitzgerald (Louise Chen)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/25/2025 | Immunovant | IMVT | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/3/2025 | Zai Lab | ZLAB | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/21/2025 | Roivant Sciences | ROIV | Maintain | Overweight (N/A) |
|
Details | ||
| 4/15/2025 | Zai Lab | ZLAB | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/11/2025 | Zai Lab | ZLAB | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/27/2025 | Zai Lab | ZLAB | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/20/2024 | Aclaris Therapeutis | ACRS | Upgrade | Overweight (Neutral) |
4.59 (4.94) |
7.63% | Details | |
| 10/2/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 9/11/2024 | Novo Nordisk | NVO | Maintain | Overweight (N/A) |
|
Details | ||
| 6/18/2024 | Inova Technology, Inc. | INVA | Maintain | Overweight (N/A) |
|
Details | ||
| 6/10/2024 | Zevra Therapeutics, Inc. | ZVRA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/30/2024 | Roivant Sciences | ROIV | Maintain | Overweight (N/A) |
|
Details | ||
| 5/17/2024 | Abbvie | ABBV | New Coverage | Overweight (N/A) |
164.35 (170.16) |
3.54% | Details | |
| 4/30/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/8/2024 | Novo Nordisk | NVO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/1/2024 | Novo Nordisk | NVO | Maintain | Overweight (N/A) |
|
Details | ||
| 12/14/2023 | Pfizer | PFE | Maintain | Overweight (N/A) |
|
Details | ||
| 12/1/2023 | Novo Nordisk | NVO | New Coverage | Overweight (N/A) |
101.84 (47.43) |
-53.43% | Details | |
| 11/14/2023 | Aclaris Therapeutis | ACRS | Downgrade | Neutral (Overweight) |
4.76 (4.94) |
3.78% | Details | |
| 10/24/2023 | Adlai Nortye Ltd. | ANL | New Coverage | Overweight (N/A) |
9.08 (10.51) |
15.75% | Details | |
| 10/16/2023 | Immunovant | IMVT | Maintain | Overweight (N/A) |
|
Details | ||
| 9/12/2023 | Lyra Therapeutics | LYRA | Maintain | Overweight (N/A) |
|
Details | ||
| 9/8/2023 | Atossa Genetics | ATOS | New Coverage | Overweight (N/A) |
0.74 (1.86) |
151.35% | Details | |
| 8/22/2023 | Aravive Inc. | ARAV | Downgrade | Neutral (Buy) |
0.22 (0.04) |
-81.82% | Details | |
| 8/10/2023 | Zai Lab | ZLAB | New Coverage | Overweight (N/A) |
26.38 (18.72) |
-29.04% | Details | |
| 6/27/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 5/19/2023 | Ambrx Biopharma | AMAM | New Coverage | Overweight (N/A) |
13.77 (28.00) |
103.34% | Details | |
| 5/12/2023 | VYNE Therapeutics | VYNE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2023 | Cutera | CUTR | Maintain | Neutral (N/A) |
|
Details | ||
| 4/5/2023 | Johnson & Johnson | JNJ | Maintain | Overweight (N/A) |
|
Details | ||
| 2/15/2023 | Immunovant | IMVT | New Coverage | Overweight (N/A) |
18.59 (37.92) |
103.98% | Details | |
| 1/11/2023 | Humanigen | HGEN | New Coverage | Neutral (N/A) |
0.16 (0.04) |
-75% | Details | |
| 1/10/2023 | TherapeuticsMD | TXMD | New Coverage | Neutral (N/A) |
5.33 (2.01) |
-62.29% | Details | |
| 1/10/2023 | Cutera | CUTR | Downgrade | Neutral (Overweight) |
31.04 (0.10) |
-99.68% | Details | |
| 12/19/2022 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 11/9/2022 | SCYNEXIS | SCYX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2022 | Avalo Therapeutics Inc. | AVTX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/3/2022 | Zoetis Inc. | ZTS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/27/2022 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2022 | SCYNEXIS | SCYX | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/26/2022 | Roivant Sciences | ROIV | Maintain | Overweight (N/A) |
|
Details | ||
| 8/30/2022 | I-Mab | IMAB | Maintain | Overweight (N/A) |
|
Details | ||
| 7/20/2022 | Johnson & Johnson | JNJ | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/13/2022 | ContraFect Corp. | CFRX | Downgrade | Neutral (Overweight) |
2.79 (0.23) |
-91.76% | Details | |
| 7/13/2022 | TherapeuticsMD | TXMD | Maintain | Neutral (Neutral) |
|
Details | ||
| 7/13/2022 | Hutchison China MediTech Ltd. | HCM | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/13/2022 | Humanigen | HGEN | Downgrade | Neutral (Overweight) |
3.02 (0.16) |
-94.7% | Details | |
| 7/7/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/22/2022 | Amarin Corporation | AMRN | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/7/2022 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/6/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/6/2022 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/2/2022 | Connect Biopharma Holdings Ltd | CNTB | New Coverage | Overweight (N/A) |
0.75 (2.31) |
208% | Details | |
| 6/1/2022 | Gracell Biotechnologies Inc | GRCL | New Coverage | Overweight (N/A) |
3.29 (10.25) |
211.55% | Details | |
| 5/24/2022 | Roivant Sciences | ROIV | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/24/2022 | Lyra Therapeutics | LYRA | New Coverage | Overweight (N/A) |
6.07 (0.50) |
-91.76% | Details | |
| 5/17/2022 | TherapeuticsMD | TXMD | Maintain | Neutral (Neutral) |
|
Details | ||
| 5/17/2022 | Spero Therapeutics | SPRO | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/16/2022 | ContraFect Corp. | CFRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/13/2022 | VYNE Therapeutics | VYNE | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/12/2022 | Aravive Inc. | ARAV | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/12/2022 | Cidara Therapeutics | CDTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/6/2022 | TherapeuticsMD | TXMD | Downgrade | Neutral (Overweight) |
0.18 (2.01) |
1016.67% | Details | |
| 5/6/2022 | Entasis Therapeutics | ETTX | Downgrade | Neutral (Overweight) |
1.91 (2.19) |
14.66% | Details | |
| 5/3/2022 | Cutera | CUTR | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/29/2022 | Roivant Sciences | ROIV | New Coverage | Overweight (N/A) |
3.86 (32.54) |
743.01% | Details | |
| 4/12/2022 | I-Mab | IMAB | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/11/2022 | Pfizer | PFE | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/8/2022 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/7/2022 | VYNE Therapeutics | VYNE | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/7/2022 | Pfizer | PFE | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/5/2022 | Merck | MRK | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/1/2022 | Johnson & Johnson | JNJ | Maintain | Overweight (N/A) |
|
Details | ||
| 3/31/2022 | Cutera | CUTR | Maintain | Overweight (N/A) |
|
Details | ||
| 3/31/2022 | Clarus | CRXT | Maintain | Overweight (N/A) |
|
Details | ||
| 3/29/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/24/2022 | ContraFect Corp. | CFRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/23/2022 | Pfizer | PFE | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/17/2022 | VYNE Therapeutics | VYNE | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/16/2022 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/10/2022 | TherapeuticsMD | TXMD | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/8/2022 | Cidara Therapeutics | CDTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/7/2022 | TherapeuticsMD | TXMD | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/7/2022 | VYNE Therapeutics | VYNE | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/4/2022 | Evolus | EOLS | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/3/2022 | Hutchison China MediTech Ltd. | HCM | Upgrade | Overweight (Overweight) |
26.19 (10.23) |
-60.94% | Details | |
| 3/3/2022 | Entasis Therapeutics | ETTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/2/2022 | Avalo Therapeutics Inc. | AVTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/1/2022 | Amarin Corporation | AMRN | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/1/2022 | Johnson & Johnson | JNJ | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/1/2022 | Humanigen | HGEN | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/24/2022 | Aclaris Therapeutis | ACRS | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/23/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/23/2022 | Cutera | CUTR | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/16/2022 | Spero Therapeutics | SPRO | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/15/2022 | Zoetis Inc. | ZTS | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/10/2022 | SCYNEXIS | SCYX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/8/2022 | Pfizer | PFE | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/3/2022 | Merck | MRK | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/3/2022 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/27/2022 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/26/2022 | Evolus | EOLS | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/25/2022 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/24/2022 | I-Mab | IMAB | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/24/2022 | Johnson & Johnson | JNJ | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/13/2022 | VYNE Therapeutics | VYNE | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/16/2021 | Pfizer | PFE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/19/2021 | Johnson & Johnson | JNJ | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2021 | VYNE Therapeutics | VYNE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/4/2021 | Zoetis Inc. | ZTS | Maintain | Overweight (N/A) |
|
Details | ||
| 9/24/2021 | Osmotica | OSMT | New Coverage | Overweight (N/A) |
2.93 (1.11) |
-62.12% | Details | |
| 9/20/2021 | Jaguar Animal Health | JAGX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/20/2021 | Clarus | CRXT | New Coverage | Overweight (N/A) |
8.81 (0.10) |
-98.86% | Details | |
| 9/13/2021 | eFFECTOR Therapeutics, Inc. | EFTR | New Coverage | Overweight (N/A) |
26.59 (0.18) |
-99.32% | Details | |
| 7/28/2021 | Hutchison China MediTech Ltd. | HCM | Maintain | Overweight (N/A) |
|
Details | ||
| 7/27/2021 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 7/13/2021 | Zoetis Inc. | ZTS | Maintain | Overweight (N/A) |
|
Details | ||
| 7/13/2021 | I-Mab | IMAB | Maintain | Overweight (N/A) |
|
Details | ||
| 7/13/2021 | Hutchison China MediTech Ltd. | HCM | Maintain | Overweight (N/A) |
|
Details | ||
| 7/13/2021 | Cutera | CUTR | Maintain | Overweight (N/A) |
|
Details | ||
| 7/7/2021 | Jaguar Animal Health | JAGX | New Coverage | Overweight (N/A) |
1.49 (2.48) |
66.44% | Details | |
| 6/28/2021 | PDS Biotechnology Corp | PDSB | New Coverage | Overweight (N/A) |
11.00 (0.93) |
-91.55% | Details | |
| 6/24/2021 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 6/11/2021 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/9/2021 | I-Mab | IMAB | Maintain | Overweight (N/A) |
|
Details | ||
| 6/4/2021 | Cerecor | CERC | New Coverage | Overweight (N/A) |
2.73 (2.93) |
7.33% | Details | |
| 6/2/2021 | Cutera | CUTR | New Coverage | Overweight (N/A) |
40.86 (0.10) |
-99.76% | Details | |
| 5/13/2021 | Soliton | SOLY | Downgrade | Neutral (Overweight) |
22.39 (22.58) |
0.85% | Details | |
| 4/16/2021 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/6/2021 | Aclaris Therapeutis | ACRS | Maintain | Overweight (N/A) |
|
Details | ||
| 4/6/2021 | Soliton | SOLY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/10/2021 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/5/2021 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/22/2021 | Evolus | EOLS | Maintain | Overweight (N/A) |
|
Details | ||
| 2/22/2021 | Humanigen | HGEN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/4/2021 | I-Mab | IMAB | Maintain | Overweight (N/A) |
|
Details | ||
| 2/2/2021 | Soliton | SOLY | Maintain | Overweight (N/A) |
|
Details | ||
| 2/2/2021 | Aclaris Therapeutis | ACRS | Maintain | Overweight (N/A) |
|
Details | ||
| 1/29/2021 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 1/26/2021 | Johnson & Johnson | JNJ | Maintain | Overweight (N/A) |
|
Details | ||
| 1/19/2021 | Aclaris Therapeutis | ACRS | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2021 | SCYNEXIS | SCYX | New Coverage | Overweight (N/A) |
7.17 (3.82) |
-46.72% | Details | |
| 1/5/2021 | Ardelyx, Inc | ARDX | New Coverage | Overweight (N/A) |
6.47 (6.47) |
0% | Details | |
| 1/5/2021 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 12/28/2020 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2020 | Zoetis Inc. | ZTS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/26/2020 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/21/2020 | Humanigen | HGEN | New Coverage | Overweight (N/A) |
13.44 (0.04) |
-99.7% | Details | |
| 9/9/2020 | Entasis Therapeutics | ETTX | New Coverage | Overweight (N/A) |
2.76 (2.19) |
-20.65% | Details | |
| 9/8/2020 | I-Mab | IMAB | Maintain | Overweight (N/A) |
|
Details | ||
| 9/8/2020 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/6/2020 | Zoetis Inc. | ZTS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/4/2020 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/3/2020 | Johnson & Johnson | JNJ | Maintain | Overweight (N/A) |
|
Details | ||
| 7/27/2020 | I-Mab | IMAB | New Coverage | Overweight (N/A) |
29.93 (4.63) |
-84.53% | Details | |
| 7/23/2020 | Pfizer | PFE | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/15/2020 | Soliton | SOLY | New Coverage | Overweight (N/A) |
7.34 (22.58) |
207.63% | Details | |
| 7/9/2020 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/15/2020 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/9/2020 | ContraFect Corp. | CFRX | New Coverage | Overweight (N/A) |
5.04 (2.79) |
-44.64% | Details | |
| 6/1/2020 | Pfizer | PFE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/22/2020 | Evolus | EOLS | Maintain | Overweight (N/A) |
|
Details | ||
| 4/28/2020 | Johnson & Johnson | JNJ | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/24/2020 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 4/14/2020 | Amarin Corporation | AMRN | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/3/2020 | Johnson & Johnson | JNJ | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/19/2020 | Pfizer | PFE | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/25/2020 | Arcutis Biotherapeutics Inc. | ARQT | New Coverage | Overweight (N/A) |
27.05 (27.03) |
-0.07% | Details | |
| 2/24/2020 | Aravive Inc. | ARAV | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/18/2020 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/12/2020 | Teva Pharma | TEVA | Maintain | Neutral (N/A) |
|
Details | ||
| 1/29/2020 | Pfizer | PFE | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/27/2020 | Aridis Pharmaceuticals | ARDS | Maintain | Overweight (N/A) |
|
Details | ||
| 1/27/2020 | Cidara Therapeutics | CDTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/23/2020 | Johnson & Johnson | JNJ | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/21/2020 | Perrigo Co. | PRGO | Maintain | Overweight (N/A) |
|
Details | ||
| 1/13/2020 | Perrigo Co. | PRGO | Maintain | Overweight (N/A) |
|
Details | ||
| 1/13/2020 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/9/2020 | Amneal Pharmaceuticals | AMRX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/9/2020 | Horizon Therapeutics | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 1/9/2020 | Bausch Health Companies | BHC | Maintain | Overweight (N/A) |
|
Details | ||
| 1/9/2020 | Zoetis Inc. | ZTS | Maintain | Overweight (N/A) |
|
Details | ||
| 1/9/2020 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 1/9/2020 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 1/9/2020 | Johnson & Johnson | JNJ | Maintain | Overweight (N/A) |
|
Details | ||
| 1/8/2020 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/8/2020 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/7/2020 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/2/2020 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 12/20/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 12/10/2019 | Aravive Inc. | ARAV | New Coverage | Overweight (N/A) |
10.73 (0.04) |
-99.63% | Details | |
| 12/2/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 12/2/2019 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/20/2019 | Johnson & Johnson | JNJ | New Coverage | Overweight (N/A) |
134.83 (240.98) |
78.73% | Details | |
| 11/14/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2019 | Horizon Pharma | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/29/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/17/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/25/2019 | TherapeuticsMD | TXMD | Maintain | Overweight (N/A) |
|
Details | ||
| 9/20/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/16/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/11/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2019 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/3/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/15/2019 | Mallinckrodt plc | MNK | Maintain | Overweight (N/A) |
|
Details | ||
| 8/15/2019 | TherapeuticsMD | TXMD | Maintain | Overweight (N/A) |
|
Details | ||
| 8/15/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2019 | Aclaris Therapeutis | ACRS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2019 | Allergen | AGN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/6/2019 | Zoetis Inc. | ZTS | Maintain | Overweight (N/A) |
|
Details | ||
| 7/31/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/29/2019 | Mylan | MYL | Maintain | Overweight (N/A) |
|
Details | ||
| 7/24/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/24/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/16/2019 | Spero Therapeutics | SPRO | Maintain | Overweight (N/A) |
|
Details | ||
| 7/12/2019 | Mallinckrodt plc | MNK | Maintain | Overweight (N/A) |
|
Details | ||
| 7/12/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/11/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/2/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/14/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2019 | Zoetis Inc. | ZTS | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2019 | TherapeuticsMD | TXMD | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2019 | Teva Pharma | TEVA | Maintain | Neutral (N/A) |
|
Details | ||
| 6/12/2019 | Perrigo Co. | PRGO | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2019 | Neos Therapeutics | NEOS | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2019 | Mylan | MYL | Maintain | Neutral (N/A) |
|
Details | ||
| 6/12/2019 | Mallinckrodt plc | MNK | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2019 | Endo International plc | ENDP | Maintain | Neutral (N/A) |
|
Details | ||
| 6/12/2019 | Cidara Therapeutics | CDTX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2019 | Amneal Pharmaceuticals | AMRX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2019 | Allergen | AGN | Maintain | Neutral (N/A) |
|
Details | ||
| 6/12/2019 | Aclaris Therapeutis | ACRS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2019 | Bausch Health Companies | BHC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/29/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/2/2019 | Teva Pharma | TEVA | Maintain | Neutral (N/A) |
|
Details | ||
| 4/8/2019 | Theravance Biopharma | TBPH | Maintain | Overweight (N/A) |
|
Details | ||
| 4/3/2019 | Horizon Pharma | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 4/2/2019 | Foamix Pharmaceuticals | FOMX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/2/2019 | Mylan | MYL | Maintain | Neutral (N/A) |
|
Details | ||
| 4/1/2019 | Zoetis Inc. | ZTS | Maintain | Overweight (N/A) |
|
Details | ||
| 4/1/2019 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 3/28/2019 | Theravance Biopharma | TBPH | Maintain | Overweight (N/A) |
|
Details | ||
| 3/28/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/25/2019 | Dermira | DERM | Maintain | Overweight (N/A) |
|
Details | ||
| 3/18/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/12/2019 | Theravance Biopharma | TBPH | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2019 | Horizon Pharma | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 2/22/2019 | Merck | MRK | New Coverage | Overweight (N/A) |
79.43 (77.85) |
-1.99% | Details | |
| 2/12/2019 | Dermira | DERM | Maintain | Overweight (N/A) |
|
Details | ||
| 2/6/2019 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 1/25/2019 | Foamix Pharmaceuticals | FOMX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/11/2019 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 12/27/2018 | Aridis Pharmaceuticals | ARDS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/30/2018 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/13/2018 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/19/2018 | Endo International plc | ENDP | Maintain | Neutral (Neutral) |
|
Details | ||
| 10/17/2018 | Zoetis Inc. | ZTS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/17/2018 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 10/17/2018 | Pfizer | PFE | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/12/2018 | Foamix Pharmaceuticals | FOMX | New Coverage | Overweight (N/A) |
5.00 (2.99) |
-40.2% | Details | |
| 10/4/2018 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/27/2018 | Heron Therapeutics | HRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/27/2018 | Teva Pharma | TEVA | Maintain | Neutral (N/A) |
|
Details | ||
| 9/26/2018 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/24/2018 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/10/2018 | Aridis Pharmaceuticals | ARDS | New Coverage | Overweight (N/A) |
13.30 (0.00) |
-100% | Details | |
| 9/7/2018 | Menlo Therapeutics | MNLO | New Coverage | Overweight (N/A) |
7.60 (1.35) |
-82.24% | Details | |
| 9/5/2018 | Dermira | DERM | Maintain | Overweight (N/A) |
|
Details |
